1468402-84-7

Basic information

• Product Name: 2',4'-difluoro-4-hydroxy-N-(4-(trifluoromethyl)phenyl)-[1,1'-biphenyl]-3-carboxamide
• Synonyms: 2',4'-difluoro-4-hydroxy-N-(4-(trifluoromethyl)phenyl)-[1,1'-biphenyl]-3-carboxamide
• CAS NO: 1468402-84-7
• Molecular Weight: 393.313
• Mol File: 1468402-84-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2',4'-difluoro-4-hydroxy-N-(4-(trifluoromethyl)phenyl)-[1,1'-biphenyl]-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2',4'-difluoro-4-hydroxy-N-(4-(trifluoromethyl)phenyl)-[1,1'-biphenyl]-3-carboxamide(1468402-84-7)
• EPA Substance Registry System: 2',4'-difluoro-4-hydroxy-N-(4-(trifluoromethyl)phenyl)-[1,1'-biphenyl]-3-carboxamide(1468402-84-7)

Safety Data

• Hazardous Substances Data: 1468402-84-7(Hazardous Substances Data)

Upstream product

• 55544-00-8 methyl 2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylate 
• 40757-09-3 methyl 2-methoxy-5-iodobenzoate 
• 455-14-1 4-trifluoromethylphenylamine 
• 344348-56-7 C₁₃H₇ClF₂O₂ 
• 119-30-2 2-hydroxy-5-iodobenzoic acid 
• 22494-42-4 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid 

Downstream Products

• 1468402-96-1 6-(2,4-difluorophenyl)-3-(4-(trifluoromethyl)phenyl)-2H-benzo[e][1,3]oxazine-2,4(3H)-dione 

Relevant articles and documents

Discovery of 5-(2′,4′-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-κ°B ligand (RANKL)-induced osteoclastogenesis

To improve the inhibitory potency of lead compound NDMC101 on RANKL-induced osteoclastogenesis, a series of new 5-(2′,4′-difluorophenyl)-salicylanilide derivatives were synthesized and evaluated for osteoclast inhibition by using TRAP-staining assay. Among them, both of compounds 6d and 6i showed three-fold increase in osteoclast-inhibitory activities compared to NDMC101 at half-inhibitory concentration. Further, the mechanistic study showed that 6d and 6i could suppress RANKL-induced osteoclastogenesis-related genes, such as NFATc1, c-fos, TRAP, and cathepsin K. Their inhibitory activities were further confirmed by including specific inhibition of NF-κ°B and NFATc1 expression levels in nucleus. In addition, 6d and 6i also could significantly attenuate bone-resorbing activity of osteoclasts by performing pit formation assay. Thus, a new class of 5-(2′,4′-difluorophenyl)-salicylanilide derivatives may be considered as essential lead structures for the further development of anti-resorptive agents.

PREPARATION AND PHARMACEUTICALS OF BIPHENYL BENZAMIDE-DERIVED DERIVATIVES

The present invention provides a biphenyl benzamide-derived derivatives, which structure is selected from formula I or formula II: and the synthesis and the application thereof.